These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 27516546)
1. Network pharmacology of JAK inhibitors. Moodley D; Yoshida H; Mostafavi S; Asinovski N; Ortiz-Lopez A; Symanowicz P; Telliez JB; Hegen M; Clark JD; Mathis D; Benoist C Proc Natl Acad Sci U S A; 2016 Aug; 113(35):9852-7. PubMed ID: 27516546 [TBL] [Abstract][Full Text] [Related]
2. JAK Inhibition Differentially Affects NK Cell and ILC1 Homeostasis. Vian L; Le MT; Gazaniga N; Kieltyka J; Liu C; Pietropaolo G; Dell'Orso S; Brooks SR; Furumoto Y; Thomas CJ; O'Shea JJ; Sciumè G; Gadina M Front Immunol; 2019; 10():2972. PubMed ID: 31921209 [TBL] [Abstract][Full Text] [Related]
3. Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models. Bottos A; Gotthardt D; Gill JW; Gattelli A; Frei A; Tzankov A; Sexl V; Wodnar-Filipowicz A; Hynes NE Nat Commun; 2016 Jul; 7():12258. PubMed ID: 27406745 [TBL] [Abstract][Full Text] [Related]
4. Role of janus kinase inhibitors in the treatment of alopecia areata. Triyangkulsri K; Suchonwanit P Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707 [TBL] [Abstract][Full Text] [Related]
5. Transcriptional, Epigenetic and Pharmacological Control of JAK/STAT Pathway in NK Cells. Scarno G; Pietropaolo G; Di Censo C; Gadina M; Santoni A; Sciumè G Front Immunol; 2019; 10():2456. PubMed ID: 31681330 [TBL] [Abstract][Full Text] [Related]
6. JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin. Wang X; Liu Q; Ihsan A; Huang L; Dai M; Hao H; Cheng G; Liu Z; Wang Y; Yuan Z Toxicol Sci; 2012 Jun; 127(2):412-24. PubMed ID: 22454431 [TBL] [Abstract][Full Text] [Related]
7. The Jakinibs in systemic lupus erythematosus: progress and prospects. Mok CC Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559 [TBL] [Abstract][Full Text] [Related]
8. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. Gadina M; Johnson C; Schwartz D; Bonelli M; Hasni S; Kanno Y; Changelian P; Laurence A; O'Shea JJ J Leukoc Biol; 2018 Sep; 104(3):499-514. PubMed ID: 29999544 [TBL] [Abstract][Full Text] [Related]
9. Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role? Kotyla PJ; Engelmann M; Giemza-Stokłosa J; Wnuk B; Islam MA Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33671049 [TBL] [Abstract][Full Text] [Related]
10. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Danese S; Grisham M; Hodge J; Telliez JB Am J Physiol Gastrointest Liver Physiol; 2016 Feb; 310(3):G155-62. PubMed ID: 26608188 [TBL] [Abstract][Full Text] [Related]
11. Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects. Flamant M; Rigaill J; Paul S; Roblin X Drugs; 2017 Jul; 77(10):1057-1068. PubMed ID: 28523588 [TBL] [Abstract][Full Text] [Related]
12. Phosphospecific flow cytometry for pharmacodynamic drug monitoring: analysis of the JAK-STAT signaling pathway. Vafadari R; Weimar W; Baan CC Clin Chim Acta; 2012 Sep; 413(17-18):1398-405. PubMed ID: 22261016 [TBL] [Abstract][Full Text] [Related]
13. Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma. Zak M; Dengler HS; Rajapaksa NS Bioorg Med Chem Lett; 2019 Oct; 29(20):126658. PubMed ID: 31522830 [TBL] [Abstract][Full Text] [Related]
14. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Schwartz DM; Kanno Y; Villarino A; Ward M; Gadina M; O'Shea JJ Nat Rev Drug Discov; 2017 Dec; 16(12):843-862. PubMed ID: 29104284 [TBL] [Abstract][Full Text] [Related]
15. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Welsch K; Holstein J; Laurence A; Ghoreschi K Eur J Immunol; 2017 Jul; 47(7):1096-1107. PubMed ID: 28555727 [TBL] [Abstract][Full Text] [Related]
16. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172 [TBL] [Abstract][Full Text] [Related]
17. Role of JAK inhibitors and immune cells in transplantation. Sailliet N; Brosseau C; Robert JM; Brouard S Cytokine Growth Factor Rev; 2019 Jun; 47():62-73. PubMed ID: 31133508 [TBL] [Abstract][Full Text] [Related]
18. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Coskun M; Salem M; Pedersen J; Nielsen OH Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161 [TBL] [Abstract][Full Text] [Related]